Evidence map›Paper›PMID 36668815›Full record

ArticleMolecular pharmaceutics2023

Amorphous Drug-Polymer Salts: Maximizing Proton Transfer to Enhance Stability and Release.

Amy Lan Neusaenger, Xin Yao, Junguang Yu, Soojin Kim, Ho-Wah Hui, Lian Huang, Chailu Que, Lian Yu

Open access · hybridAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Amy Lan NeusaengerSchool of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, United States.ORCID 0000-0001-9862-2104
Xin YaoSchool of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, United States.ORCID 0000-0002-7657-4997
Junguang YuSchool of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, United States.ORCID 0000-0001-6458-8307
Soojin KimSchool of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, United States.
Ho-Wah HuiDrug Product Development, Bristol Myers Squibb, Summit, New Jersey 07901, United States.
Lian HuangDrug Product Development, Bristol Myers Squibb, Summit, New Jersey 07901, United States.
Chailu QueDrug Product Development, Bristol Myers Squibb, Summit, New Jersey 07901, United States.
Lian YuSchool of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, United States.ORCID 0000-0002-4253-5658
University of Wisconsin–Madison · USBristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amorphous drug-polymer salt (ADPS) can be remarkably stable against crystallization at high temperature and humidity (e.g., 40°C/75% RH) and provide fast release. Here, we report that process conditions strongly influence the degree of proton transfer (salt formation) between a drug and a polymer and in turn the product's stability and release. For lumefantrine (LMF) formulated with poly(acrylic acid) (PAA), we first show that the amorphous materials prepared by slurry conversion and antisolvent precipitation produce a single trend in which the degree of drug protonation increases with PAA concentration from 0% for pure LMF to ∼100% above 70 wt % PAA, independent of PAA's molecular weight (1.8, 450, and 4000 kg/mol). This profile describes the equilibrium for salt formation and can be modeled as a chemical equilibrium in which the basic molecules compete for the acidic groups on the polymer chain. Relative to this equilibrium, the literature methods of hot-melt extrusion (HME) and rotary evaporation (RE) reached much lower degrees of salt formation. For example, at 40 wt % drug loading, HME reached 5% salt formation and RE 15%, both well below the equilibrium value of 85%. This is noteworthy given the common use of HME and RE in manufacturing amorphous formulations, indicating a need for careful control of process conditions to ensure the full interaction between the drug and the polymer. This need arises due to the low mobility of macromolecules and the mutual hindrance of adjacent reaction sites. We find that a high degree of salt formation enhances drug stability and release. For example, at 50% drug loading, an HME-like formulation with 19% salt formation crystallized faster and released only 20% of the drug relative to a slurry-prepared formulation with 70% salt formation. Based on this work, we recommend slurry conversion as the method for preparing ADPS for its ability to enhance salt formation and continuously adjust drug loading. While this work focused on salt formation, the impact of process conditions on the molecular-level interactions between a drug and a polymer is likely a general issue for amorphous solid dispersions, with consequences on product stability and drug release.

Indexed as

PolymersProtonsChemistry, PharmaceuticalDrug CompoundingDrug StabilityLumefantrineSaltsSolubilityLumefantrinePolymersProtonsSaltsamorphous drug−polymer saltdissolutionlumefantrinephysical stabilitypoly(acrylic acid)tropical conditions

Identifiers

PMID36668815
PMCPMC9906740
OpenAlexW4317556115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.